Perrigo acquires U.K. firm Galpharm
This article was originally published in The Tan Sheet
Executive Summary
The Allegan, Mich.-based private labeler announces Jan. 9 the $86 million acquisition of Galpharm Healthcare Ltd, an OTC store-brand drug supplier based in Yorkshire, U.K. Perrigo says it anticipates adding $55 million to its sales annually. The acquisition "further expands our global presence" and "complements our existing U.K. business," Perrigo Chairman and CEO Joseph Papa says in a release...
You may also be interested in...
Perrigo U.K. Trades Supplements Business In For Additional OTC Operations
Perrigo U.K. is getting out of the supplement business and adding to its OTC portfolio with a recent reverse agreement with NeutraHealth
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.